Next Article in Journal
“Ain’t She a Bute?”: The Importance of Proper History Taking in a Case of Inappropriate Use of Horse NSAID in a Human
Previous Article in Journal
Clinically Malignant Breast Lesion in an Adolescent Girl: A Case Report
Review

Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer

1
Department of Medicine, MetroWest Medical Center, Tufts University School of Medicine, Framingham, MA 01702, USA
2
Department of Medicine, Mayo Clinic, Rochester, MN 55902, USA
3
Department of Medical Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
4
Division of Medical Oncology, Hematology and Palliative Care, University of Wisconsin, Madison, WI 53706, USA
*
Author to whom correspondence should be addressed.
Clin. Pract. 2021, 11(3), 441-454; https://doi.org/10.3390/clinpract11030059
Received: 8 May 2021 / Revised: 12 June 2021 / Accepted: 2 July 2021 / Published: 6 July 2021
Small-cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by a rapid initial response and early development of resistance to systemic therapy and radiation. The management of SCLC significantly changed for the first time in decades with the introduction of immune checkpoint inhibitors. Pembrolizumab, a humanized IgG4 isotype antibody, targets the programmed cell death protein 1 (PD-1) pathway to restore anti-tumor immunity. Prospective trials of pembrolizumab in patients with previously treated SCLC showed significant durability of responses. These results led to the U.S. Food and Drug Administration (FDA) granting pembrolizumab accelerated approval as second- or third-line monotherapy for patients with extensive-stage (ES) SCLC. In a recent clinical trial that included patients with previously untreated ES-SCLC, pembrolizumab in combination with platinum/etoposide met its progression-free survival endpoint, but overall survival (OS) did not cross the threshold for superiority. With the therapeutic landscape for SCLC rapidly evolving, we review prior experience and future directions of pembrolizumab in ES-SCLC. View Full-Text
Keywords: small-cell lung cancer; pembrolizumab; immunotherapy; PD-1; checkpoint inhibitor small-cell lung cancer; pembrolizumab; immunotherapy; PD-1; checkpoint inhibitor
MDPI and ACS Style

Riano, I.; Patel, S.R.; Liu, S.V.; Duma, N. Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer. Clin. Pract. 2021, 11, 441-454. https://doi.org/10.3390/clinpract11030059

AMA Style

Riano I, Patel SR, Liu SV, Duma N. Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer. Clinics and Practice. 2021; 11(3):441-454. https://doi.org/10.3390/clinpract11030059

Chicago/Turabian Style

Riano, Ivy, Shruti R. Patel, Stephen V. Liu, and Narjust Duma. 2021. "Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer" Clinics and Practice 11, no. 3: 441-454. https://doi.org/10.3390/clinpract11030059

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop